A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors
Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, Indiana, United States, 46202Contact: Mateusz Opyrchal, MD         NYU LangoneNew York, New York, United States, 10016Contact: Salman Punekar, MD         University of Texas MD Anderson Cancer CenterHouston, Texas, United States, 77030Contact: Sarina Piha-Paul, MD         Fujian Cancer HospitalFuzhou, Fujian, China, 350014Contact: Jingfeng Liu, MD         Henan Cancer HospitalZhengzhou, Henan, China, 450003Contact: Qiming Wang, MD         Hunan Cancer HospitalChangsha, Hunan, China, 410031Contact: Jing Wang, MD         Shandong Cancer HospitalJinan, Shandong, China, 250117Contact: Yuping Sun, MD         The First Affiliated Hospital of Zhejiang University School of MedicineHangzhou, Zhejiang, China, 310003Contact: Jianzhong Shentu, MD         

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 26, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments